<DOC>
	<DOCNO>NCT01715831</DOCNO>
	<brief_summary>This multicenter , open-label , single-arm extension study evaluate long-term safety tocilizumab ( RoActemra/Actemra ) participant Rheumatoid Arthritis ( RA ) . Participants complete MA21488 ( NCT00810199 ) core study ML21530 ( NCT00754572 ) study could benefit study drug , accord opinion investigator , receive 8 milligram per kilogram ( mg/kg ) intravenous ( IV ) tocilizumab every 4 week . The anticipated time study treatment 104 week .</brief_summary>
	<brief_title>A Long-term Safety Extension Study Tocilizumab Brazilian Participants With RA Having Completed Studies ML21530 And MA21488</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Participants complete last visit ML21530 MA21488 core study might benefit treatment use study drug accord investigator 's evaluation Absence adverse event ( AE ) current recent laboratory find would prevent use 8 mg/kg dose tocilizumab Receiving outpatient treatment For woman postmenopausal surgically sterile : agreement use least one adequate method contraception Participants prematurely discontinue ML21530 MA21488 core study reason MA21488 study participant remain untreated tocilizumab 's discontinuation accord treatmentfree remission criterion MA21488 study Immunization live/attenuated vaccine since last administration study drug ML21530 ML21488 core study Diagnosis last visit study ML21530 last visit study MA21488 rheumatic autoimmune disease RA , include systemic erythematous lupus ( SEL ) , mixed connective tissue disease ( MCTD ) , scleroderma polymyositis , significant systemic involvement secondary RA ( e.g. , vasculitis , pulmonary fibrosis Felty 's syndrome ) . Secondary Sjogren 's Syndrome and/or nodulosis RA allow Diagnosis last visit ML21530 study last visit MA21488 study rheumatic autoimmune disease and/or inflammatory joint disease rheumatoid arthritis Abnormal laboratory parameter baseline History severe allergic anaphylactic reaction humanize murine monoclonal antibody Evidences concomitant , serious uncontrolled illness Known active condition history recurrent infection bacteria , virus , fungi , mycobacteria agent Evidence active malignant disease , malignancy diagnose last 10 year breast cancer diagnose last 20 year Uncontrolled disease status , asthma inflammatory bowel disease acute crises usually treat oral parenteral corticosteroid Current hepatic disease , determine Investigator Active tuberculosis ( TB ) require treatment previous three year . Participants screen latent TB accord local practice guideline admit study latent TB detect . Participants must present evidence active TB infection enrollment . Participants treat tuberculosis without recurrence three year allow History drug abuse since inclusion ML21530 MA21488 core study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>